🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-521962-83-00
Authorised Phase I/II

AdaptNK –Cell Therapy for High-risk Myeloid Disease

2025-521962-83-00 · tracked via the Priya Life Science EU tracker
Sponsor
Karolinska Institutet
Sponsor type
Educational Institution
Therapeutic area
Hemic and Lymphatic Diseases
Decision date
19/01/2026
Enrollment target
26
Sites
Sweden

Condition studied

Relapsed and/or refractory AML or MDS

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521962-83-00 on CTIS ↗ ← All trials in the EU